Skip to Main Content

A Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Pretreated Metastatic Triple Negative Breast Cancer

Conditions

Breast

Phase II

What is the purpose of this trial?

This study will investigate the safety and efficacy of TIL therapy in patients with metastatic TNBC who have progressed on at least one and no more than three prior systemic anticancer therapies.

  • Trial with
    Yale Cancer Center
  • Start Date
    12/22/2019
  • End Date
    12/31/2021
Trial Image

For more information about this study, contact:

Alexandra Dormal

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    06/01/2020
  • Study HIC
    #2000025837